Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19

Affiliations

• ¹ Division of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland; Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland. Electronic address: francois.girardin@chuv.ch.
• ² Infectious Diseases Service and Transplantation Centre, Lausanne, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland.
• ³ Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland; Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom.
• ⁴ Division of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland.